直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

Unexpected Results Should Be Commensurate with the “Full Scope” of the Claims

April 12, 2021

Authored and Edited by Kyu Yun Kim; Thomas Lee Irving; Brooke M Wilner; Stacy Lewis*

Holding

In Daikin Indus., Ltd v. Chemours Co. FC, LLC, No. 2020-1616, 2021 WL 717017 (Fed. Cir. Feb. 24, 2021), the Federal Circuit panel of Judges Lourie, Wallach, and Chen affirmed a decision of the Patent Trial and Appeal Board (Board), finding claims 1-5 of U.S. Pat. No. 9,574,123 (the ’123 patent) unpatentable as obvious.

Background

Daikin Industries, Ltd (Daikin) owns the ’123 patent, directed to mixtures of hydrofluorocarbons (HFCs), hydrofluoroolefins (HFOs), and one or more of a chlorofluorocarbon (CFC), hydrochlorofluorocarbon (HCFC), chloromethane (HCC), and/or 3,3,3-trifluoropropyne (TFP). Daikin, 2021 WL 717017 at *1. The ’123 patent purports to solve the poor lubrication issue of HFCs and HFOs by adding TFP or one or more chlorine-containing compounds—i.e., CFCs, HCFCs, or HCCs. Id.

Claim 1 of the ’123 patent, the only independent claim at issue, reads:

  1. A composition comprising HFC and HFO, wherein the composition comprises:

1) HFC-32, HFC-125, HFC-134a, and HFC-134 as the HFC;

2) at least one of HFO-1234yf and HFO-1234ze as the HFO;

3) at least one member selected from the group consisting of HCC-40, HCFC-22, HCFC-124, CFC-115, HCFC-1122, CFC-1133, and 3,3,3-triflouropropyne as a third component.

The Board Found the Claims Obvious

The Chemours Company FC, LLC (Chemours) petitioned for inter partes review of all five claims of the ’123 patent. Id. at *2. Chemours challenged the claims as obvious in view of International App. Pub. No. WO 2015/077134 (Van Horn) in combination with U.S. Pat. Pub. No. 2015/0322317 (Collier) in view of a 2014 Air-Conditioning, Heating, and Refrigeration Institute (AHRI) Standard. Id.

There was no material dispute that Van Horn and Collier collectively disclosed all the elements in the challenged claims. Id. at *2. The Board's obviousness analysis focused on:

(1) whether a skilled artisan would have recognized Collier’s preferred HFO-1234yf embodiment, containing small amounts of HCC-40 and/or CFC-115, as a substitute for the HFO-1234yf in Van Horn's mixture;

(2) whether a skilled artisan would have been otherwise motivated to combine Collier's HFO-1234yf with Van Horn's mixture; and

(3) whether any unexpected increases in lubricity related to the claimed invention should be accorded substantial weight in the obviousness inquiry. Id.

With respect to each question, the Board concluded (1) Yes, (2) Yes, and (3) No. Id. at *3.

The Board noted that both Van Horn and Collier “disclose refrigeration as a primary application for their compositions,” and Collier’s HFO-1234yf was similar or nearly identical in purity to Van Horn’s HFO-1234yf, as taught by the AHRI Standard. Id. Also, the Board found that at the time of the invention it was known that at least some chlorine-containing refrigerants had increased lubricity compared to compounds without chlorine, and that the mechanism by which lubricity was affected was known or suspected. Id. Accordingly, the Board concluded that a skilled artisan would have been motivated to combine Collier’s HFO-1234yf with Van Horn's mixture to increase lubricity. Id. The Board then rejected Daikin’s nonobviousness argument based on unexpected results because the test results failed to show increased lubricity for the full scope of the claimed inventions. Id.

Accordingly, the Board issued its Final Written Decision finding the challenged claims unpatentable as obvious. Chemours Co. FC, LLC v. Daikin Indus., Ltd., 2020 WL 402064 at *1 (P.T.A.B. Jan. 23, 2020).

Federal Circuit Affirmed the Board’s Decision

Daikin appealed to the Federal Circuit. On appeal, Daikin first argued that the Board violated the Administrative Procedure Act by finding the claims unpatentable based on grounds not advanced in the petition. Daikin, 2021 WL 717017 at *3. The Court disagreed, concluding that the petition properly set forth a substitution theory. Id. Daikin further contested the substantive obviousness analysis of the Board. Id.

Substitution Analysis

The Court disagreed with Daikin that a skilled artisan would have been dissuaded from substituting Collier’s HFO-1234yf for Van Horn’s because of the unpredictability of certain unspecified refrigerant properties, such as deleterious effects on the resulting mixture’s ODP/GWP, safety, reliability, and performance properties. Id. at *4.

The Court pointed out that Daikin itself argued that the proposed substitution would lead to predictable changes in the properties of Van Horn's mixture. Id. Also, the Court noted that such predictability was supported by expert testimony. Id. The Court held that the Board’s factual determinations underlying its substitution analysis were supported by substantial evidence. Id. at *5.

Unexpected Results

Daikin further argued that, even if the Board did not err in its substitution analysis, the claimed compositions exhibit an unexpected increase in lubricity, and that such unexpected results overcome any evidence of obviousness. Id. The Court disagreed. Id.

But the Court held that any purported unexpected lubricity increase disclosed was not commensurate with the full scope of the claimed invention. Id. In particular, each comparison test disclosed in the ’123 patent involved mixtures comprising only 0.5 mass percent of the third component, but the claims permit the third component to comprise nearly all of the mixture (e.g., claims 1 and 3–5). Id. More importantly, the Court noted “the Board's findings that lubricity increases from the addition of chlorine-containing compounds were expected,” and that Daikin failed to submit any evidence that the magnitude of any increased lubricity was unexpected. Id.

The Court therefore affirmed the Board’s conclusion, holding that Daikin’s proffered objective indicia of nonobviousness failed to overcome the evidence of obviousness. Id.

Take-Away

This case provides a cautionary tale to practitioners: evidence of unexpected results, used to support nonobviousness, should be commensurate with “the full scope” of the claimed invention to overcome prima facie obviousness. When presenting unexpected results of the claimed invention to overcome a finding of prima facie obviousness, practitioners should carefully consider whether the proffered testing data fairly represent the entire scope of the claims. In addition, if relying on unexpected results, practitioners should take care to explain why such results were unexpected.

Tags

Obviousness (35 USC § 103), Patent Trial and Appeal Board (PTAB)

Related Practices

Appeals, Issues, and Legal Strategy

Federal Circuit and Supreme Court Appeals

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Related Industries

Chemicals, Industrials, and Materials

Manufacturing

Related Offices

Atlanta, GA

Washington, DC

*Stacy Lewis is a Law Clerk at Finnegan.

Copyright © 2021 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 



DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Webinar

Changes at the PTAB from Settled Expectations to Real Parties in Interest to Director Involvement

May 18, 2026

Webinar

Conference

Best Practices and Tech in Intellectual Property Conference 2026

May 17, 2026

Tel Aviv

Articles

COPPA’s Amended Rule Is Now in Full Effect: What Operators Need to Know

May 15, 2026

Seminar

IP Strategy at the Crossroads: Technology, Enforcement, and Contracts

May 15, 2026

Taipei

Federal Circuit IP Blog

When “and” and “e.g.” Matter: Federal Circuit Revives VLSI vs. Intel Case

May 14, 2026

INCONTESTABLE® Blog

Netflix Prevails in Copyright Infringement Suit Regarding Tiger King

May 14, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP